Most biotech and pharma creative dies in review – either gutted into something no patient reads, or rejected outright and sent back to start. Winston Francois builds patient education, HCP detail aids, and DTC campaign creative with MLR requirements built into the first draft, not bolted on after rejection. The result: fewer review rounds, faster launches, creative that still converts.
The Problem
Agencies Design for the Brief, Not the Review Committee
Most creative agencies build a concept, present it to your team, get sign-off, then hand it to MLR for the first time. That's when Legal flags the claim language, Regulatory flags the fair balance, and Medical flags the mechanism-of-action statement nobody checked with clinical. Three departments who've never seen the work now have veto power over a deliverable everyone thought was done. The agency wasn't in the room for any of it, so every note turns into a change order and a new invoice.
Watered-Down Creative That Clears Review But Doesn't Convert
The fastest way to get something through MLR is to strip every claim down to what's already in the label. That produces creative that's technically compliant and functionally useless – patient brochures that read like package inserts, HCP leave-behinds with no reason for a physician to remember the brand. Your team ships it because the launch date is fixed, then wonders why engagement numbers look nothing like the category benchmarks.
Every Review Round Costs You a Launch Window
A single MLR round-trip on a piece with real claims can run one to two weeks depending on committee cadence. Creative that wasn't built for review typically needs three to four rounds before it clears – a full quarter burned on assets that should have shipped in a month. If the piece is tied to a conference, a formulary decision, or a competitor launch, that delay isn't just annoying, it's a missed window that doesn't come back.
Freelancers and Boutique Shops Don't Know Claims Substantiation
Most creative talent has never had to defend a headline against a Regulatory reviewer or explain why a statistic needs a reference footnote and a specific font size. So they treat every MLR note as a surprise instead of anticipating it, and your in-house team ends up doing the actual regulatory writing while the agency collects the retainer. You're paying for creative execution and getting compliance triage.
How We Help
We start by auditing your last 6-12 months of MLR submissions – not the creative itself, but the review notes. What gets flagged every time. Which reviewer kills which claim types. How many rounds your average asset takes and where the friction actually sits – Legal, Medical, or Regulatory. Most teams have never looked at this pattern because it lives in email threads and PromoMats comments, not a single document. We pull it into one and use it to build the constraints before we design anything.
From there we build a claims library specific to your assets – what's substantiated, what needs a reference, what phrasing has cleared before and what hasn't. Every concept we bring to your team already carries the substantiation a reviewer will ask for, so the first MLR submission looks like a near-final draft instead of a rough cut. This is the single biggest lever for cutting review rounds – not faster creative, better-prepared creative.
For patient education, we write for health literacy and MLR at the same time. That means plain-language explanations of mechanism and condition that still carry the required fair balance and risk language, laid out so the required text doesn't visually compete with the message that actually gets read. We test drafts against your fair balance requirements before the first formal submission, not after.
For HCP detail aids and leave-behinds, we work from the approved core claims and build variations a rep can actually use in an eight-minute call – visual hierarchy that leads with the clinical data point that matters, not the one that was easiest to clear. We build these knowing sales wants something a physician remembers, and Medical wants something defensible, and we design for both requirements from the same draft.
DTC campaign creative gets the same treatment: concepts built around your approved indication and label language, not generic disease-awareness stock creative. We write headlines and calls to action that survive claims review because we already know which comparative language and outcome statements your MLR committee has approved before, and which it hasn't.
Every asset gets tracked through two numbers we report on: rounds-to-approval and days-to-approval, benchmarked against your prior 12 months. If a piece still takes four rounds, we want to know why and fix the workflow, not just the asset. On the demand side we track engagement by asset type – detail aid pull-through with reps, patient material completion rates, DTC creative performance by channel – so you know which approved creative is actually working, not just which creative got approved.
What we deliver
- MLR-Ready Claims Library – a documented set of substantiated claims, approved phrasing, and reference requirements your creative team draws from instead of guessing.
- Patient Education Materials – plain-language brochures, leave-behinds, and digital content built for health literacy and fair balance from the first draft.
- HCP Detail Aids and Leave-Behinds – sales materials built around your approved core claims, designed for an eight-minute call and a Medical review at the same time.
- DTC Campaign Creative – disease-awareness and branded campaign concepts built on label-approved language, designed to survive claims review without losing the hook.
The teams that win the review cycle aren't the ones with the boldest creative – they're the ones who put MLR in the room on day one instead of day thirty.
Our Methodology
We run creative production in 90-day sprints because that's roughly one full MLR cycle for a meaningful set of assets – long enough to build a claims library and ship a first wave, short enough that your team sees output before the quarter ends. Sprint one is the audit and claims library. Sprint output is a working set of approved assets, not a strategy deck.
Inside each sprint we run creative and review in parallel instead of sequentially. Draft concepts go to a pre-review checkpoint with your internal MLR contact before they ever hit the formal committee, which is where most of the round-reduction happens. It's a small process change – one extra checkpoint – but it's the difference between MLR seeing a near-final draft and MLR seeing a first draft.
We don't take over your MLR relationship or your regulatory function. We build creative that's easier for your existing committee to approve, and we hand off a claims library and workflow your internal team keeps using after the engagement ends.
How We Work
First 30 days: we audit your last two quarters of MLR submissions and interview your Legal, Medical, and Regulatory reviewers to find out what actually gets flagged. We build the claims library and ship a first batch of pre-reviewed concepts for your highest-priority asset type – usually whichever one has the worst review history.
Days 31-60: full production on the priority asset category, with concepts pre-checked against the claims library before formal MLR submission. We start tracking rounds-to-approval against your historical baseline so you can see the difference in real numbers, not estimates.
Days 61-90: we expand into the second and third asset categories – typically moving from patient materials into HCP or DTC creative – and hand off the claims library and pre-review checklist to your internal team so the workflow keeps running without us in the room.
Team is small on purpose: a creative lead who's worked inside pharma review before, a writer who owns claims substantiation, and a project lead who runs the weekly sync with your MLR contact. We meet weekly during active production, monthly once the workflow is handed off. No account team, no separate strategy division billing separately – the people doing the work are the people in the room.
- Fewer MLR review rounds per asset, tracked against your prior submission history
- Faster time from creative brief to approved, shippable asset
- A claims library and pre-review workflow your internal team keeps using after the engagement
If your biotech & pharma company needs creative production leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does biotech and pharma creative production with MLR built in cost?
Most engagements run $15,000 to $40,000 per month depending on how many asset categories we're producing across – patient materials, HCP detail aids, and DTC creative each add scope. Pricing is a flat monthly retainer, not per-asset billing, because per-asset pricing incentivizes agencies to minimize review rounds by minimizing ambition.
How long before we see fewer MLR review rounds?
The claims library and pre-review checkpoint go live in the first 30 days, and you'll see the difference on the first asset batch submitted after that – typically within the first 60 days of the engagement. Full impact across all asset categories usually shows up by day 90, once the workflow has run through a full sprint on each category.
Do you replace our creative agency or work alongside them?
Either works. Some clients bring us in to run creative production directly, others keep an existing agency for brand campaigns and use us specifically for regulated asset types – patient education, HCP materials, DTC claims creative – where MLR experience matters more than general creative chops.
How is this different from hiring a pharma-specialist creative agency?
Most pharma-specialist agencies are still agencies – they staff a creative team, present concepts, then react to MLR notes after the fact. We build the claims library and pre-review checkpoint into the production process itself, so the review committee is seeing near-final work on the first submission instead of a first draft.
How do you measure ROI on this?
Two numbers: rounds-to-approval and days-to-approval, both benchmarked against your prior 12 months of submissions. On the demand side we track engagement by asset type – detail aid pull-through with your sales team, patient material completion rates, DTC creative performance by channel – so you can see which approved creative is actually being used, not just which creative cleared review.
What kind of company is the right fit for this?
Series A to growth-stage biotech and pharma companies with at least one asset in commercial or late-stage clinical use, an active MLR committee, and a creative backlog that's stuck in review. If you don't have an MLR process yet, or you're pre-clinical with no commercial assets, this isn't the right engagement – talk to us about brand strategy first.
